Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Gebruik van anti-IL-6 in tweede en derde trimester van de zwangerschap
dec 2024 | JIA, RA, Virale infecties